Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Maximilian TscharreFlorian EggerMatthias MachataMiklos RohlaNadia MichaelManuel NeumayrRobert ZweikerJohannes HajosChristopher AdlbrechtMarkus SuppanWolfgang HelmreichBernd EberKurt HuberThomas W WeissPublished in: PloS one (2017)
Despite a high level of care, a considerable number of patients were not treated with the more potent P2Y12-inhibitors. Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel.
Keyphrases
- percutaneous coronary intervention
- acute coronary syndrome
- newly diagnosed
- end stage renal disease
- antiplatelet therapy
- ejection fraction
- healthcare
- st segment elevation myocardial infarction
- chronic kidney disease
- acute myocardial infarction
- atrial fibrillation
- coronary artery disease
- palliative care
- st elevation myocardial infarction
- coronary artery bypass grafting
- heart failure
- pain management
- patient reported outcomes
- health insurance